Description of Medical Areas
About the FDA Approved Listings
|
 |
Approved Drugs for Cardiology/Vascular Diseases
Drugs Approved in 2008
No approvals recorded for Cardiology/Vascular Diseases in 2008.
Drugs Approved in 2007
Azor (amlodipine besylate; olmesartan medoxomil); For the treatment of hypertension; Daiichi Sankyo; Approved September 2007
Fenofibrate; For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia; LifeCycle Pharma; Approved August 2007
Letairis (ambrisentan); For the treatment of pulmonary arterial hypertension; Gilead; Approved June 2007
Soliris (eculizumab); For the treatment of paroxysmal nocturnal hemoglobinuria; Alexion Pharm; Approved March 2007
Drugs Approved in 2006
Ranexa (ranolazine); For the treatment of chronic angina in patients failing first-line therapy; CV Therapeutics; Approved January 2006
Drugs Approved in 2005
Drugs Approved in 2004
Drugs Approved in 2003
Crestor (rosuvastatin calcium); For the treatment of primary hypercholesterolemia (heterozygous
familial and nonfamilial) and mixed dyslipidemia; AstraZeneca; Approved August 2003
Levitra (vardenafil); For the treatment of erectile dysfunction related to sexual activity in men; Bayer, GlaxoSmithKline; Approved September 2003
Drugs Approved in 2002
Altocor (lovastatin) Extended-Release Tablets; Oral tablets for the adjuctive treatment of hypercholesterolemia; Andrx; Approved June 2002
Benicar; Oral tablet for the treatment of hypertension; Sankyo Pharma; Approved April 2002
Imagent (perflexane lipid microspheres); Ultrasound contrast agent for improved imaging of the heart; Alliance Pharmaceutical; Approved June 2002
Inspra (eplerenone tablets); Oral tablets for the treatment of high blood pressure.; Pharmacia; Approved September 2002
Plavix (clopidogrel bisulfate); For the treatment of acute coronary syndrome; Sanofi-Synthelabo; Approved February 2002
Remodulin (treprostinil); For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms; United Therapeutics; Approved May 2002
Drugs Approved in 2001
Advicor (extended-release niacin/lovastatin); For the treatment of cholesterol disorders; Kos Pharmaceuticals; Approved December 2001
Natrecor (nesiritide); For the treatment of patients with acutely decompensated congestive heart failure; Scios; Approved August 2001
Teveten HCT (eprosartan mesylate/hydrochlorothiazide); Tablets for the treatment of hypertension; Unimed Pharmaceuticals; Approved November 2001
TriCor (fenofibrate) tablets; For the treatment of primary hypercholesterolemia, mixed lipidemia and hypertriglyceridemia; Abbott Laboratories; Approved September 2001
Drugs Approved in 2000
Angiomax (bivalirudin); For patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA); Medicines Company; Approved December 2000
Argatroban Injection; Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.; Texas Biotechnology Corporation, SmithKline Beecham; Approved June 2000
Atacand HCT; For the treatment of hypertension; AstraZeneca; Approved September 2000
Betapace AF Tablet; For treatment of the irregular heartbeats in patients with atrial fibrillation; Berlex Laboratories; Approved February 2000
Diltiazem HCL, Extended-Release Capsules; For the reduction of high blood pressure; Biovail Laboratories; Approved January 2000
Innohep (tinzaparin sodium) injectable; For the treatment of acute symptomatic deep vein thrombosis; Dupont Pharmaceuticals; Approved July 2000
Lescol XL (fluvastatin sodium) tablet, extended release; For the use as an adjunct to diet to reduce elevated total cholesterol; Novartis; Approved October 2000
Micardis (hydrochlorothiazide; telmisartan) Tablet; For the treatment of hypertension; Boehringer Ingelheim; Approved November 2000
Nitrostat (nitroglycerin) Tablets; For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.; Parke-Davis; Approved May 2000
Drugs Approved in 1999
Lescol (fluvastatin sodium) capsules, Rx; Treatment for the reduction of triglycerides; Novartis; Approved June 1999
Mevacor (lovastatin) tablets; Treatment for primary prevention of coronary heart disease; Merck; Approved March 1999
Niaspan; Niacin extended-release tablets; Kos Pharmaceuticals; October 28, 1999
Drugs Approved in 1998
Agrylin; Treatment for Thrombocythemia; Roberts Pharmaceutical; Approved December 1998
Atacand; Treatment for hypertension; Astra Merck; Approved June 1998
Atacand (R) (candesartan cilexetil); Treatment for hypertension; Astra Merck; Approved June 1998
CellCept; Treatment for the prevention of organ rejection inpatients undergoing heart transplants; Roche; Approved February 1998
Diovan HCT; Treatment for hypertension; Novartis; Approved March 1998
Integrilin; Injection of eptifibatide; COR Therapeutics, Key Pharmaceuticals; Approved May 1998
Micardis; Treatment for Hypertension; Boehringer Ingelheim; Approved November 1998
Rythmol; Treatment for paroxysmal atrial fibrillation; Knoll Pharmaceutical; Approved January 1998
Tiazac; Treatment for chronic stable angina; Forest Laboratories; Approved February 1998
Tiazac; Treatment for chronic stable angina; Forest Laboratories; Approved February 1998
Tricor; Treatment for very high triglyceride levels; Abbott Laboratories; Approved February 1998
Viagra; Treatment for impotence; Pfizer; Approved March 1998
Drugs Approved in 1997
Baycol (cerivastatin sodium); Treatment for high cholesterol; Bayer; Approved June 1997; withdrawn 8/8/01
Captopril and hydrochlorotiazide; Generic equivalent of Capozide; Mylan Laboratories; Approved (tentatively) May 20, 1997
Captopril and hydrochlorotiazide; Treatment for hypertension; Mylan Laboratories; Approved May 1997
Cardizem (R) (Diltiazem HC1 for injection) Monvial (R); Delivery system for Monovial; Hoechst Marion Roussel; Approved September 1997
Corlopam; Treatment for severe high blood pressure; Neurex; Approved September 1997
Diovan; Oral capsules and tablets for the treatment of hypertension; Novartis; Approved January 1997 (capsules); July 2001 (tablets)
Diovan (valsartan); Treatment for hypertension; Ciba Pharmaceuticals; Approved January 1997
DynaCirc CR; Treatment for hypertension; Novartis; Approved February 1997
EDEX; Treatment for erectile dysfunction; Schwarz Pharma; Approved June 1997
Lescol; Treatment for coronary atherosclerosis; Novartis; Approved September 1997
Lexxel (enalapril maleate-felodipine ER); Treatment for hypertension; Astra Merck; Approved January 1997
Microzide (hydrochlorothiazide); Treatment for mild-to moderate hypertension; Watson Pharmaceuticals; Approved January 1997
Normiflo; Treatment for deep venous thrombosis; Wyeth-Ayerst Laboratories; Approved May 1997
Pentoxifylline; Generic equivalent of Trental; Faulding, Mylan Laboratories; Approved July 1997
Pindolol; Generic equivalent of Visken; Teva Pharmaceutical; Approved April 1997
PLAVIX; Treatment for cardiac atherosclerotic events; Sanofi, Bristol-Myers Squibb; Approved November 1997
Posicor; Treatment for hypertension and chronic stable angina pectoris; Roche; Approved June 1997
ReoPro; Treatment for cardiac ischemic complications; Centocor; Approved November 1997
REPRONEX(menotropins for injection, USP); Generic equivalent of Pergonal; Ferring Pharmaceuticals; Approved February 1997
Teveten; Treatment for hypertension; SmithKline Beecham; Approved December 1997
Verapamil; Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR; IVAX; Approved December 1997
Warfarin Sodium tablets; Generic equivalent of Coumadin; Barr Laboratories; Approved March 1997
Zocor; Treatment for high cholesterol; Merck; Approved November 1997
Drugs Approved in 1996
Covera-HS (verapamil); Treatment for hypertension and angina; G.D. Searle, Alza; Approved January 1996
Mavik (trandolapril); Treatment for hypertension; Knoll Pharmaceutical; Approved May 1996
Muse; Treatment for impotence; Vivus; Approved October 1996
|
|
Back to Centerwatch Drug Approvals
|
